Search

Displaying results 591 - 600 of 2955 in total
  1. Drug

    Candesartan cilexetil

    go.drugbank.com/drugs/DB00796
    ApprovedInvestigational

    Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is administered orally as the prodrug, candesartan cilexetil, which is rapidly converted to its active metabolite,...

    Mixtures: Nra-candesartan Hctz, Nra-candesartan HctzProducts: Nra-candesartan, CANDESARTAN EG
  2. Drug

    Adapalene

    go.drugbank.com/drugs/DB00210
    ApprovedInvestigational

    On December 8th, 2008, Galderma Labs gained FDA approval for Epiduo®, a 0.1% adapalene, 2.5% BPO combination gel.[L12873] … [A193518] Differin®, produced by Galderma Labs, was first granted FDA approval on May 31st, 1996, as a 0.1% adapalene topical solution.

  3. Drug

    Bendamustine

    go.drugbank.com/drugs/DB06769
    ApprovedInvestigational

    Bendamustine is a nitrogen mustard drug which has been used in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL). Bendamustine is a bifunctional mechlorethamine derivative capable of formi...

    Products: BENDAMUSTINA EG
  4. Drug

    Drometrizole trisiloxane

    go.drugbank.com/drugs/DB11585
    Approved

    being generally recognized as safe and effective for over-the-counter sunscreen use [L2795, F82]. … The compound is a lipophilic benzotriazole derivative marketed as Meroxyl XL by L'Oreal, although sunscreens with drometrizole trisiloxane are currently only approved for use in the EU, Canada, Australia

  5. Drug

    Pralsetinib

    go.drugbank.com/drugs/DB15822
    ApprovedInvestigational

    Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. … [A202049, A202055, L15986] Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment

  6. Drug

    Sodium bicarbonate

    go.drugbank.com/drugs/DB01390
    ApprovedInvestigational

    Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions.

    Mixtures: Ora Rinse Liq, E-Z-gas IIProducts: BICARBONATO DE SODIO EN POLVO - 45
  7. Drug

    Piperaquine

    go.drugbank.com/drugs/DB13941
    ApprovedInvestigational

    It has come back into use in combination with the artemisinin derivative [DB11638] as part of the combination product Eurartesim [FDA Label].

  8. Drug

    Telmisartan

    go.drugbank.com/drugs/DB00966
    ApprovedInvestigational

    Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinit...

    Mixtures: Nra-telmisartan/hctz, Nra-telmisartan/hctzProducts: Nra-telmisartan, TELMISARTAN EG
  9. Drug

    Triclabendazole

    go.drugbank.com/drugs/DB12245
    ApprovedInvestigational

    This drug is currently the only FDA-approved drug for individuals with fascioliasis, which affects 2.4 million people worldwide.[A174988,L5452] … Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.

  10. Drug

    Fluoroestradiol F-18

    go.drugbank.com/drugs/DB15690
    ApprovedInvestigational

    [A203912] Fluoroestradiol F-18 was first granted FDA approval in May 2020, and will be developed by PETNET Solutions, Inc. and Zionexa USA under the brand name Cerianna. … [L14096] The ability to image ER-positive tumors _in vivo_ is advantageous in that, while helping to visualize tumor progression/regression, it may also be used to assess for heterogeneity in ER expression